Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06354322
Other study ID # APHP230630
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 2024
Est. completion date May 2034

Study information

Verified date April 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Sophie GEORGIN-LAVIALLE, Professor
Phone 00 33 1 56 01 72 04
Email sophie.georgin-lavialle@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with autoinflammatory diseases (AID) have recurrent episodes of systemic inflammation accompanied by nonspecific elevation of blood inflammation markers typically absent between attacks. A complication of autoinflammatory diseases is AA amyloidosis, which can lead to renal failure and dialysis. Advances in genetic analysis have led to the identification of new autoinflammatory diseases and thus new pathophysiological pathways. However, genetic analyses are sometimes confronted with results that are difficult to interpret. These are the Variants of Unknown Significance, for which genetic analysis alone does not allow to determine if the genetic mutation is responsible for the symptoms. genetic analysis sometimes has limitations in the diagnosis of AID which can only be overcome by pathophysiological studies of the variants found.


Description:

The study aim to explore variants of undetermined significance in major and minor patients with unclassified autoinflammatory disease or AA amyloidosis of undetermined etiology by studying their pathogenicity. National multicenter research: internal medicine department of Tenon Hospital, pediatric department of Versailles Hospital and pediatric dermatology department of Necker Enfants Malades Hospital in Paris Samples will be collected at the inclusion visit or at subsequent visits of the patient to the department during a blood draw performed as part of routine care by a registered nurse. The total volume of the sample will be 24 mL per 6 month period maximum, and will not exceed In case of skin involvement of the auto-inflammatory disease, a skin biopsy may be performed as part of the patient's follow-up care.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date May 2034
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 3 Years to 80 Years
Eligibility Inclusion Criteria: Inclusion criteria for patients to be studied: - Patients over 18 years of age with the capacity to give express free and informed consent and; - Minor patients under 18 years of age with both parents or legal guardians giving consent; - Patients with unclassified IAD or AA amyloidosis of undetermined etiology; - Patients followed in one of the study departments; - Patients weighing more than 15 kg. Inclusion criteria for control patients: - Patients over 18 years of age with the capacity to give free and informed express consent; - Patients with IAD classified with well-defined international criteria or ; - Patients who have undergone cosmetic surgery or blood donors). Exclusion Criteria: - Patients unable to give express free and informed consent; - Subjects under guardianship, curatorship or safeguard of justice; - Subjects who do not speak French; - Subjects unable to answer questions or express themselves; - Patients weighing less than 15 kg; - Patients without social security coverage

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type Measure Description Time frame Safety issue
Primary Exploration of VUS in AutoInflammatory Diseases To explore variants of undetermined significance (VUS)in patients with unclassified autoinflammatory disease or AA amyloidosis of undetermined etiology by studying their pathogenicity. Up to 4 years
Secondary Pathophysiology of Autoinflammatory Diseases To improve the knowledge on the pathophysiology of Autoinflammatory Diseases: to determine the role of new inflammation pathways in AutoInflammatory Diseases Up to 4 years
Secondary Role of other innate immune cells in AutoInflammatory Diseases Evaluate the role of other innate immune cells (neutrophils, mast cells...) and their mediators Up to 4 years
Secondary Improve knowledge of AA amyloidosis Improve knowledge of AA amyloidosis, a complication of autoinflammatory diseases Up to 4 years
See also
  Status Clinical Trial Phase
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Recruiting NCT05383339 - Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
Recruiting NCT00059748 - Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
Not yet recruiting NCT06293924 - Pericardial Fluid Analysis in Recurrent Pericarditis
Not yet recruiting NCT05292768 - Are Mast Cells Involved in Autoinflammatory Diseases
Not yet recruiting NCT06435468 - Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases N/A
Recruiting NCT06004349 - Autoimmune and Autoinflammatory Genetics Study